Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) EBIT Margin (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed EBIT Margin for 6 consecutive years, with 929.41% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 459119.0% to 929.41% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1315.38% through Dec 2025, up 347230.0% year-over-year, with the annual reading at 1315.38% for FY2025, 347230.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 929.41% at TScan Therapeutics, up from 1475.59% in the prior quarter.
  • The five-year high for EBIT Margin was 296.17% in Q4 2023, with the low at 6364.55% in Q2 2024.
  • Average EBIT Margin over 5 years is 1595.12%, with a median of 646.74% recorded in 2021.
  • The sharpest move saw EBIT Margin crashed -558279bps in 2024, then soared 510795bps in 2025.
  • Over 5 years, EBIT Margin stood at 497.62% in 2021, then decreased by -21bps to 602.55% in 2022, then skyrocketed by 51bps to 296.17% in 2023, then crashed by -1764bps to 5520.6% in 2024, then surged by 83bps to 929.41% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 929.41%, 1475.59%, and 1256.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.